Clinical Trial
Anti-CD137 and Anti-CTLA-4 Monoclonal Antibody in Patient With Advanced Cancer
Investigator
Complete title:
A Phase 1 Study of AGEN2373, an Anti-CD137 Monoclonal Antibody, as Monotherapy and in Combination with AGEN1181, an Fc-engineered Anti-CTLA-4 Monoclonal Antibody, in Patients with Advanced Cancer
Trial phase:
Phase
I
Study ID:
NCT04121676
Local study ID:
RG1122190
Summary:
This study is an open-label, Phase 1, multicenter study to evaluate the safety, tolerability, PK, and PD profiles of AGEN2373 as a monotherapy and in combination with AGEN1181, and to assess the maximum tolerated dose (MTD) in subjects with advanced solid tumors.
Trial keywords:
Neoplasms, Advanced Malignant
Enrollment status:
Recruiting
Trial eligibility
** For Eligibility information, please click on the "Look up trial at NIH" link above **
Other eligibility criteria may apply.
Other eligibility criteria may apply.
Learn more
Whether you are eligible for a research study depends on many things. There are specific requirements to be in research studies. These requirements are different for each clinical trial.
Disclaimer: We update this information regularly. However, what you read today may not be completely up to date.
Contact us
For more information about Fred Hutch and to schedule an appointment.
